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The Consensus Coding Sequence (CCDS) collaboration involves curators at multiple centers with a goal of producing a
conservative set of high quality, protein-coding region annotations for the human and mouse reference genome assem-
blies. The CCDS data set reflects a ‘gold standard’ definition of best supported protein annotations, and corresponding
genes, which pass a standard series of quality assurance checks and are supported by manual curation. This data set
supports use of genome annotation information by human and mouse researchers for effective experimental design,
analysis and interpretation. The CCDS project consists of analysis of automated whole-genome annotation builds to iden-
tify identical CDS annotations, quality assurance testing and manual curation support. Identical CDS annotations are
tracked with a CCDS identifier (ID) and any future change to the annotated CDS structure must be agreed upon by the
collaborating members. CCDS curation guidelines were developed to address some aspects of curation in order to improve
initial annotation consistency and to reduce time spent in discussing proposed annotation updates. Here, we present the
current status of the CCDS database and details on our procedures to track and coordinate our efforts. We also present the
relevant background and reasoning behind the curation standards that we have developed for CCDS database treatment
of transcripts that are nonsense-mediated decay (NMD) candidates, for transcripts containing upstream open reading
frames, for identifying the most likely translation start codons and for the annotation of readthrough transcripts.
Examples are provided to illustrate the application of these guidelines.
Database URL: http://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi
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Introduction
One of the fundamental aspects of an organism’s genome
is its genes, which provide the instructions for the produc-
tion of both mRNAs that encode proteins and functional
noncoding RNAs involved in regulation of gene expression
and protein-coding gene translation. Many researchers rely
on human and mouse genome annotation for the design
and interpretation of experiments. Several such data sets
exist produced by both manual and automated protocols
that may employ different methods and standards for
annotation, as well as different sources of input sequence
data. There is often a trade-off between coverage and ac-
curacy and therefore one must decide how conservative a
set to use. However, it is difficult to compare methods and
protocols used by different annotation groups and pipe-
lines, and challenging to determine if different genome
annotation browsers are displaying identical annotation in-
formation or alternate interpretations of the underlying
primary data. It is important to be aware of alternate an-
notation information in order to choose the most appropri-
ate data set for further analysis or experimental design.
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.............................................................................................................................................................................................................................................................................................In order to address this issue, the Consensus Coding
Sequence (CCDS) project (1) provides a conservative set of
consensus protein-coding sequences for human and mouse.
The nature of the project promotes collaboration be-
tween annotation groups from different institutions—the
National Center for Biotechnology Information (NCBI),
the Wellcome Trust Sanger Institute (WTSI), the European
Bioinformatics Institute (EBI) and the University of
California Santa Cruz (UCSC). All groups contribute in differ-
ent ways to the project: three groups provide the genome
annotation data sets (EBI, WTSI and NCBI); three groups pro-
vide curation review (NCBI, WTSI and UCSC) and two groups
support quality assurance tests for the CCDS data set (NCBI
and UCSC). Ensembl annotations (2), a joint project between
WTSI and EBI, include both automated predictions from a
computational annotation process and manual annotations
from the Human and Vertebrate Analysis and Annotation
(HAVANA)group(3,4)(WTSI),whereastheNCBIannotations
include RefSeq records (5, 6) produced from both manual
and automated annotations. Thus, curation support is an in-
tegral factor supporting the NCBI and Ensembl genome an-
notation data sets, and for the CCDS data set. The high
confidence CCDS reference set is built based on comparison
of NCBI and Ensembl genome annotation data to identify
identical CDS genomic coordinates (same start and stop
codons, same splice site coordinates). The annotation must
also pass a number of stringent quality assurance tests. The
CCDSdatasetisprovidedasperiodicspecies-specificcompre-
hensive releases; however, there is also an ongoing coordi-
nated review process that contributes annotation
modifications and additions to the NCBI and Ensembl
genome annotation data set and to the CCDS build process.
It is important to note that manual curation supports the
data set but not all CCDS IDs have been curated, and that
theCCDSprojectisconservativewhichisbothastrengthand
weakness. For example, some known genes are excluded
from the data set when the assembled genome sequence
cannot support annotating the correct CDS, and some con-
sistently annotated CDS regions are intentionally removed
from the CCDS data set if there are quality concerns (as
described below).
Status of the CCDS data set
CCDS builds occur whenever the human or mouse genomes
are re-annotated by NCBI, coupled with timing consider-
ations for Ensembl data set releases. Re-annotation occurs
at irregular intervals to update annotation on the same
assembly, or when a new genome assembly is released.
The most recent CCDS comparative analysis was on the
human genome with results released on 7 September
2011. Compared with the previous annotation comparison
analysis (released in April 2011), the human CCDS data set
increased by 909 CCDS IDs, which includes adding
additional protein isoforms for genes that were already
represented in the data set with at least one CCDS ID, as
well as adding representation for 64 Gene IDs that were
not previously included (Table 1). Mouse has 137 more
genes with a CCDS ID than human but has fewer CCDS
IDs overall, so fewer alternative splice variants are included
in the mouse CCDS data set. This is due to more focused
curation on human genome annotation than on mouse.
TheCCDSdatasetsizecontinuestoincreasewitheachana-
lysis based on both the computational genome annotation
updates, which integrate new data sets submitted to the
International Nucleotide Sequence Database Collaboration
(INSDC, http://www.insdc.org/), and on ongoing curation
activities thatsupplement orimprove upon thatannotation.
Quality assurance testing for the
CCDS database
In order to ensure that consensus coding sequences are of
high quality, multiple quality assurance (QA) tests are done.
While each of the collaborating groups independently per-
forms QA tests in their annotation pipelines, an additional
layer of QA tests are applied to the set of identified match-
ing genome annotations prior to accepting them and as-
signing a CCDS ID (Table 2). Candidate annotations that fail
these QA tests undergo a round of manual checking, which
provides feedback that may be useful to the NCBI and
Ensembl automatic annotation pipelines, may result in im-
proved QA tests and may result in a curatorial decision to
reject annotation matches based on the QA failure or
rescue a match based on biological knowledge of an excep-
tion category. For example, manual review of QA results for
earlier analysis runs resulted in a QA override decision for
selenocysteine proteins which were flagged with an error
for internal stop codons. These tests continue to identify
some CDS annotations added by automatic processes
based on new primary data submissions that likely do not
represent bona fide coding sequences; these annotations
are rejected from the CCDS database.
Table 1. Status of current CCDS builds (as of 7 September
2011)
Organism ! Human
(Build 37.3)
Mouse
(Build 37.2)
GeneIDs 18471 19508
CCDS IDs 26473 22187
Public CCDS IDs
a 26400 21921
Genes with >1 CCDS ID 4999 1986
Genes with >6 CCDS IDs 76 15
aPublic CCDS IDs are all those that are not currently under review
or pending an update or withdrawal
.............................................................................................................................................................................................................................................................................................
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.............................................................................................................................................................................................................................................................................................Some QA tests look for possible contraindications within
the coding sequence and its annotated structure that may
include identifying issues with the genome sequence. Other
types of QA tests assess the quality of the annotation match
between the NCBI and Ensembl genome annotation data
sets, assess the coding potential for the annotated CDS,
assess the possibility that the annotated CDS is more
likely a pseudogene and reconcile the annotation data set
with current information, especially with regard to genes
that have been withdrawn or changed to a non-coding
type. Basic integrity checks on the protein products repre-
sented ensures that the proteins represented with a CCDS
ID have consistent matching in their reading frames and
sequences, not merely in genome annotation coordinates.
Some sequence differences are expected and tolerated due
to a major difference between the NCBI and EBI/WTSI an-
notation strategies. NCBI reference genome annotation is
generated by aligning known RefSeq transcript records to
the genome, which is then supplemented by calculating
new annotations based on primary sequence data in the
INSDC database. In contrast, the manual and computational
annotations in the Ensembl data set are direct annotations
on the reference genome. Since the NCBI known RefSeq
transcript and protein set is generated using transcript
data (supplemented with some publication support and
personal communications), these records may have some
sequence differences, typically small polymorphisms, com-
pared with the reference genome sequence. The majority
of RefSeq proteins included in the CCDS data set are iden-
tical to the translation derived from the genome sequence,
with a total of 781 CCDS IDs (1.6% of the data set) repre-
senting curatorial decisions to retain sequence differences
in associated RefSeq proteins based on abundance of sup-
port evidence, conservation and publication data. The CCDS
database, therefore, has some tolerance for minor differ-
ences between the NCBI and EBI/WTSI annotations (though
Table 2. Types of CCDS QA tests performed prior to acceptance of CCDS candidates
CCDS QA test
a Test purpose
Subject to NMD Checks for transcripts subject to NMD
b, which are unlikely to be coding
Quality low Checks for low coding propensity
Has non-consensus splice sites Checks for non-canonical splice sites
c
Predicted pseudogene Checks for genes that are predicted to be pseudogenes by UCSC
d
Ortholog not found/not conserved Checks for genes that are not conserved (UCSC calculation) and/or are not in a HomoloGene
cluster
e
Too short Checks for transcripts or proteins that are unusually short, typically <100 amino acids
RefSeq is not an NP_ Checks if the RefSeq has model (XP_) status; only NCBI matches with NP_ IDs are permitted
as CCDS ID accessions
CDS start or stop not in alignment Checks for a start or stop codon in the reference genome sequence
Internal stop Checks for the presence of an internal stop codon in the genomic sequence; possibly a
selenocysteine codon or ribosomal frameshift
Length mismatch versus genome Checks if the protein encoded by the reference genome sequence is the same length as the
matching annotation sequences
NCBI:Ensembl protein length different Checks if the protein encoded by the NCBI RefSeq is the same length as the EBI/WTSI protein
Low percent identity versus genome Checks for >99% overall identity between the matching annotations and the genomic-
encoded protein
NCBI:Ensembl low percent identity Checks for >99% overall identity between the NCBI and EBI/WTSI proteins
Accession dead Checks if an associated RefSeq is no longer valid
GeneID changed Checks if the GeneID has been changed
Gene discontinued Checks if the GeneID is no longer valid
Not protein coding Checks if the GeneID no longer has a protein-coding locus type
More than one GeneID represented Checks for accessions associated with >1 GeneID; allowed only for readthrough genes that
encode the same protein as an individual gene
aAll tests are performed following the annotation comparison step of each CCDS build and are independent of individual annotation
group QA tests performed before the annotation comparison.
bWhen the stop codon occurs >50nt upstream of the last splice site (7, 8).
cSplice donor-acceptor pairs other than GT-AG, GG-AG and AT-AC.
dPredicted retrotransposed genes (9).
eNCBI’s database for the automated detection of homologs (http://www.ncbi.nlm.nih.gov/homologene/).
.............................................................................................................................................................................................................................................................................................
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these differences being due to sequence polymorphisms
between the reference genome sequence and the tran-
script data or publication support the RefSeq is based on.
Review process and curation
An important part of maintaining the integrity of the CCDS
database is the constant review of the data, and the ability
to make necessary changes to the represented CCDS IDs,
which may involve either update or withdrawal of the
CCDS ID. Unlike most individual databases, where usually
a unilateral curatorial decision is made on a given represen-
tation as per the policies of the particular database, the
CCDS database is unique in that the review process must
be carried out by multiple collaborators, and agreement
must be reached before any changes are made. This
multi-collaborator involvement in turn contributes to data
accuracy and quality and it underscores the ‘gold standard’
definition of the CCDS data set.
Achieving consensus among multiple collaborators pre-
sents a challenge, and thus it is necessary to have a good
collaborator coordination system that includes a work pro-
cess flow and forums for analysis and discussion. The CCDS
database, therefore, operates an internal website that
serves multiple purposes including curator communication,
collaborator voting, providing special reports and tracking
the status of CCDS representations. For example, the in-
ternal website reports CCDS IDs that have been flagged
for review by any group for a potential annotation
update or withdrawal, tracks CCDS IDs that were recently
updated or withdrawn and need an explanatory public
note and provides a variety of reports ranging from QA
analysis during a CCDS build to reports of all CDS annota-
tions that do not yet have a CCDS ID (Prospective CCDS).
When a collaborating CCDS group member identifies a
CCDS ID that may need review, a voting process is em-
ployed to decide on the final outcome (Figure 1). Voting
is tracked on the internal CCDS website and is carried out
by the manual curation groups, RefSeq and HAVANA, as
well as by the UCSC group that acts as an independent
voice. A consensus agreement is needed to proceed with
an annotation update that will alter the CDS structure at a
start or stop codon or a splice donor or acceptor site or to
withdraw a CCDS ID. In the event of conflicting votes, which
may occur due to different curation policies or alternative
interpretation of data, further discussion of associated data
and/or publications takes place until an agreement can be
reached on the CCDS representation. This is supported by
an e-mail issue tracking system (Atlassian JIRA) that facili-
tates tracking a discussion over time, uploading images
or files to support a position or retrieving the history of a
discussion for a similar case. The same system is used to
support enquiries submitted by public users of the CCDS
resource via the provided Contact page (http://www.ncbi.
nlm.nih.gov/projects/CCDS/UserRequest/UserRequest.cgi).
The process of discussing conflicts results in one or more
groups modifying their vote in the CCDS internal curation
system to reflect the final consensus agreement to update
or withdraw a CCDS ID. Each manual annotation group
then applies the update independently (i.e. NCBI updates
a RefSeq transcript and HAVANA manually updates
genome annotation). These updates are integrated into
the genome annotation processes at NCBI and Ensembl,
resulting annotation is compared and the CCDS analysis
process confirms the update and increments the version
number of the CCDS ID. If agreement cannot be reached
for an update due to either ambiguous support data
or different requirements for support evidence by the
RefSeq and HAVANA groups, then the default is to with-
draw the CCDS ID. In this case, annotation may continue to
be provided by one or both annotation groups; however,
the annotation is not considered sufficiently supported to
be retained in the CCDS database.
Why are curation guidelines
necessary?
During manual curation sprints of the CCDS data set, we
noticed that some types of manual annotation updates
were conflicting between the collaborating groups at a
higher frequency, resulting in time-consuming discussions
in order to reach agreement. Upon review of the annota-
tion guidelines that were already established by the RefSeq
and HAVANA curation groups, it became apparent that
these conflicts were often due to either contradictory
curation guidelines, or incomplete guidelines. Therefore,
it was desirable to establish a common set of curation
guidelines to optimize consistency and to minimize the
need for further discussions. Although the CCDS collabor-
ation members share the common goal of achieving con-
sistent annotation for protein-coding genes, several factors
make this a challenge. First, each member of the CCDS col-
laboration also employs curation guidelines that were in-
dependently developed to address the full spectrum of
annotation needs by those groups (broader than the
scope of the CCDS collaboration). Second, the collaboration
involves multiple annotators working at very different lo-
cations from each other. CCDS curation guidelines were
therefore established after careful discussion including
review of the current literature and are available on the
CCDS website. The established guidelines are oriented
toward addressing those annotation details that resulted
in a higher frequency of conflicting annotation or that con-
sistently required lengthy discussion to reach agreement.
These guidelines are used for ongoing curation between
CCDS builds and curators refer to specific sections when
.............................................................................................................................................................................................................................................................................................
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more complex case with conflicting opinions. The curation
policies established for the CCDS data set have been inte-
grated into the RefSeq and HAVANA annotation guidelines
and thus, new annotations provided by both groups are
more likely to be concordant and result in addition of a
CCDS ID. It is important to note that these standards ad-
dress specific problem areas, are not a comprehensive set of
annotation guidelines, and do not restrict the annotation
policies of any collaborating group.
Currently, we have established guidelines for: (i) non-
sense-mediated mRNA decay (NMD) candidates, (ii) inhibi-
tory upstream open reading frames, (iii) annotation of
translation start sites where there is more than one possible
start codon and (iv) management of protein-coding read-
through transcripts. The CCDS curation guidelines are
based on known biological principles, experimental results
reported in the literature and literature-based guidelines
related to current understanding of what ‘typically’ occurs
in vivo at the transcript and protein production levels.
Figure 1. The flowchart outlines the CCDS review process (light gray boxes). CCDS IDs undergo status changes during and
following the review process, as indicated by the colored boxes, where light green indicates ‘Public’ status, red indicates
an ongoing review that has not yet reached consensus, orange indicates a pending update or withdrawal that has reached
consensus, and purple indicates ‘Withdrawn’ status.
.............................................................................................................................................................................................................................................................................................
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.............................................................................................................................................................................................................................................................................................In many cases, the only definitive solution to a question
regarding validity of a distinct protein isoform inferred
from aligned transcripts (or an inference regarding the cor-
rect translation start site) is experimental data that shows
production of specific protein isoforms. In the absence of
experimental evidence, curators make an educated infer-
ence based on our established guidelines as to the most
likely correct CDS representation while acknowledging in
a public note that there may be other interpretations.
Curation challenges and guidelines
NMD
NMD is a eukaryotic surveillance pathway that destroys
abnormal transcripts containing a premature termination
(or stop) codon (PTC) that encode a truncated protein (for
reviews, see 10–12). If translated, the resulting aberrant
protein may cause disease. The NMD process has a large
body of associated research (see reviews), but less is
known about the features that the cellular machinery
uses to decide whether a transcript should enter the NMD
pathway. Different models have been suggested to explain
NMD, including the exon junction complex (EJC) model and
the ‘faux 30–UTR’ model (13, 14), but none of these models
are entirely satisfactory for explaining when NMD occurs
(15, 16). It has been reported that NMD is widespread
and  45% of human genes have one isoform that is tar-
geted by NMD (7, 8), and for many of these, the pathway is
acting to regulate gene expression.
Consequently, NMD is a major consideration for CCDS
protein representations, and therefore, we have estab-
lished curation guidelines to address this issue. A conserva-
tive approach is taken for assessing the potential of
transcripts to be NMD candidates and potentially produce
non-functional proteins. Using the EJC model, if the stop
codon is >50nt upstream of the last exon–exon junction,
then the transcript is assumed to be an NMD candidate.
Any CDS annotation based on such a transcript is excluded
from the CCDS data set except in the following circum-
stances: (i) If all transcripts at the locus are NMD candidates
but the locus is known to be protein coding, then one of
these transcripts will be represented in the CCDS data set
and (ii) If there is experimental evidence demonstrating
that a functional protein is produced from such a transcript.
Historically, NMD candidate transcripts were represented
in the CCDS data set as they were annotated as protein
coding by both RefSeq and HAVANA. However, this policy
was later revised to exclude them from the CCDS data set
unless there is evidence for the protein, as indicated above,
and proteins associated with NMD transcripts were flagged
for review to withdraw them from the CCDS data set.
For example, CCDS8237.1, which represented the human
KLHL35 gene, was annotated based on the mRNA
AK091109.1, which retains an intron introducing a PTC, so
it was identified as an NMD candidate after curation
guidelines were established (Figure 2). Given the lack of
experimental evidence for the protein predicted on this
transcript, this CCDS ID was withdrawn. In contrast,
CCDS53542.1 representing the human DUSP13 gene is an
example of an NMD exception that was retained in the
data set because there is publication support (17) for pro-
tein production from the CDS.
Consequently, additions to the CCDS data set of this type
do not occur by chance because there are established cri-
teria for when a CDS annotation associated with an NMD
transcript may be included in the CCDS data set. The RefSeq
group also revised its annotation policy such that proteins
are only represented for NMD transcripts according to the
CCDS guidelines, and all other NMD transcripts are repre-
sented as non-coding (with the putative ORF annotated
with a misc_feature, see NR_003256.2). The HAVANA pro-
ject has different goals and annotates these transcripts with
a CDS and tags them as NMD candidates for researchers
who need them for designing experiments, particularly
those in the proteomics field.
Upstream open reading frames
Another consideration for the CCDS data set is the presence
of upstream open reading frames (uORFs) that reside up-
stream of the main or primary ORF (pORF) (reviewed in 18,
19). The scanning model for translation states that the small
(40S) ribosomal subunit scans the mRNA starting from the
50-end and then initiates from the first translation start
codon (20), thereby making it possible that a uORF could
be translated first, which could then subject the transcript
to NMD. In mammals, it is thought that as many as 25% of
the genes possess uORFs (21), which may encode bioactive
peptides, but it is known that many uORF-containing tran-
scripts can still produce the protein product from the down-
stream pORF. For example, the human CD1C transcript
(RefSeq NM_001765.2, VEGA OTTHUMT00000046351 and
Ensembl ENST00000368170 associated with CCDS1175.1)
contains four uORFs encoding peptides ranging from 3 to
29 amino acids, one of which has a strong Kozak signal, yet
translation of the longer 333 amino acids downstream ORF
occurs to produce a functional protein (22). This may be
explained by other studies showing that short ORFs of
18–20 codons tend to be resistant to NMD, with 35 amino
acids being the approximate size limit for uORFs that
escape NMD due to re-initiation of ribosomes at a down-
stream translation start codon (20, 23, 24).
It is thought that uORFs likely play a role in translational
regulation and tend to reduce, but not abolish, translation
and that longer uORFs that have a strong Kozak context
are more inhibitory (18–20, 25). As with NMD, it would fa-
cilitate annotation if there were experimental data avail-
able for assessing the impact of each uORF, but currently
.............................................................................................................................................................................................................................................................................................
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published data is available. A recent genome-wide study
showed that upstream ORFs inhibit translation but do not
completely abolish it (25). However, the data set in this
study was not large enough to provide enough statistical
power to study the effect of combinations of features on
gene expression and so effects of single features were ana-
lyzed in turn, e.g. uORFs with strong Kozak signals were
analyzed independently of longer length uORFs, whereas
CCDS curators need to consider the combined effects of
these features and also the combined effects of multiple
uORFs. Additional genome-wide data could therefore facili-
tate annotation of transcripts with uORFs. Although such
data are lacking, we still need to have a joint CCDS policy
to address cases where transcripts have uORFs that all
groups can agree upon. Currently, the annotation guide-
lines document includes policies regarding annotation of
coding regions based on transcripts containing uORFs
which have a strong Kozak signal and are either  35
amino acids or overlap the pORF. These standards were
generated following a review of the literature early on in
our collaboration and include consideration of the uORF
length, Kozak sequence strength and whether the uORF
overlaps the pORF. In light of recent publications, this is
an area that is currently under discussion and we anticipate
revising the CCDS guidelines in the future.
Multiple in-frame translation start sites
As mentioned above, the scanning model states that the
ribosome will initiate translation from the first start
codon with a favorable context that it encounters
when scanning from the 50-end of an mRNA sequence
(20, 26, 27) which provides the premise for assuming
that translation usually starts from the first AUG, e.g.
preproinsulin, CCDS7729.1. Translation initiation is influ-
enced by several factors including the length of the 50
leader sequence (26), uORFs, hairpin secondary structure
near the translation initiation site (20, 28, 29) and the
sequence context around the translation initiation site.
A favorable start codon context is defined based on the
Kozak signal for which there is an optimal sequence
(gccGCCACCAUGG for vertebrates) (30), although this
can vary and a G or A at position  3a n daGa t+ 4
makes the strongest contribution to the context (where
the ‘A’ of the AUG is +1) (20, 27). The presence of a U at
the +5 position is also thought to negate the effect of G
at the +4 position (20, 31). Therefore, the CCDS collabor-
ators define the sequence [A/G]NNaugG[not U] as a
strong Kozak signal, with any other sequence being con-
sidered a weak Kozak signal.
Exceptions to the rule of translation from the first AUG
involve three mechanisms—ribosome re-initiation, leaky
scanning and the use of upstream non-AUG start codons
Figure 2. UCSC Genome Browser view of the human KLHL35 (kelch-like 35) gene. CCDS8237.1 was based on AK091109.1 (mRNA
track, blue). This CCDS ID has now been withdrawn because a retained intron introduces a premature termination codon,
rendering the transcript an NMD candidate. CCDS44685.2 representing the completely processed full-length variant remains
valid for this gene.
.............................................................................................................................................................................................................................................................................................
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stream ORF; distance between the upstream and down-
stream ORFs is important since the ribosome needs time
to gain another Met-tRNAi-eIF-2 that is necessary for rec-
ognition of an AUG codon (27). A second exception occurs
if the AUG is not in a strong Kozak context which may
permit leaky scanning (20) by the ribosome, which bypasses
this AUG to start translation from a downstream start
codon. Potentially, multiple different proteins could be pro-
duced from one mRNA and this has been experimentally
confirmed for some transcripts (20, 32).
The CCDS guidelines stipulate that the longest ORF
should be annotated unless there is compelling evidence
that indicates translation initiation from an internal AUG
is more likely. The CCDS database represents one transla-
tion start site per CCDS ID with the goal to represent the
more likely translation initiation site. Thus, if curators think
it is possible that additional start codons may be used for
translation, this is indicated in a CCDS public note (e.g.
CCDS28818.2 representing the mouse Vegfa gene). The cur-
rent CCDS guidelines are based on principles of the scan-
ning model for translation as discussed above, and they also
include considerations for experimental evidence, commu-
nity standards for start codon annotation, conservation of
the start codon and the presence of protein domains or
localization signals.
CCDS4929.1 representing the human CRISP3 (cysteine-
rich secretory protein 3) gene is an example of how the
AUG guidelines were applied (Figure 3). This CCDS ID was
originally based on the mRNA X95240.1, and the 50-most
AUG in that transcript was selected as the start codon.
However, compared with other available transcript data,
this transcript is 50-partial and its first exon does not
extend far enough to include an upstream AUG found in
other transcripts. The collaborators, therefore, voted to
update this CCDS ID to version 2 to extend the 50-end of
Figure 3. UCSC Genome Browser view of CCDS4929.1, which was updated to version 2, representing a variant of the human
CRISP3 (cysteine-rich secretory protein 3) gene. The CDS was extended at the 50-end. (a) Both the longer protein (258 amino
acids) encoded by the update and the shorter protein (245 amino acids) have predicted signal peptides (SignalPv4.0) of 32 amino
acids and 19 amino acids, respectively. (b and c) Base-level view. The upstream AUG start codon (b) has the weaker Kozak
context (blue box) and is only conserved among primates (red box), whereas the downstream AUG (c) is conserved among more
mammals (46-way alignment and conservation track).
.............................................................................................................................................................................................................................................................................................
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mRNA AK292786.1 and increasing the encoded protein
length by 13 amino acids. The CRISP3 gene product
is known to be secreted (33). The protein predicted from
both start sites has a predicted signal peptide (SignalPv4.0).
The upstream AUG has a weak Kozak sequence and ap-
pears to be primate-specific, whereas the downstream
AUG has a stronger Kozak sequence and it is conserved
among more mammals. Since there is some conservation
of the upstream AUG and the signal peptide for the
longer protein is a reasonable size, it is reasonable to an-
notate the upstream AUG as the start of the CDS and there-
fore the update was approved. Nonetheless, since the
upstream AUG has a weak Kozak signal, it is possible that
ribosomes may initiate translation from the downstream
start codon at some frequency due to leaky scanning, and
both start codons could be used in vivo.
Readthrough transcripts
The CCDS collaboration has established guidelines for the
treatment of a special class of transcripts, known as read-
through transcripts. Readthrough transcripts arise when
transcription initiates in one gene, continues past the
normal transcription termination signals for that gene,
and terminates within or at the end of a downstream
gene on the same strand. Readthrough transcripts may
span two or more genes in the same genomic neighbor-
hood. Splicing generates a mature transcript that includes
exons from each gene, and may include novel exons from
the intergenic region. Such transcripts may encode a fusion
protein derived from exons of each gene, or the coding
sequence may be in-frame with one gene and have frame-
shifts with respect to the other gene(s), or the readthrough
transcript may possibly be non-coding due to NMD. The
biological function of readthrough transcripts and/or
the encoded products is not yet understood. While the def-
inition of ‘readthrough’ has been described elsewhere (34),
the CCDS collaboration definition of readthrough is very
specific in that the individual partner genes must be dis-
tinct, and the readthrough transcripts must share  1 exon
(or  2 splice sites except in the case of a shared terminal
exon) with each of the distinct shorter loci. Unlike the
broader definition of ‘conjoined’ genes described by
Prakash et al. (34), the CCDS collaboration readthrough
definition does not include cases where the genes are
otherwise considered to be co-transcribed (e.g. human
HOXC4, HOXC5 and HOXC6) (35), bicistronic (e.g. human
CERS1 and GDF1) (36), overlapping each other but not shar-
ing splice sites (e.g. the 30 exon of the mouse Mon1b gene
overlaps the 50 exon of the Syce1l gene) or genes that have
nested arrangements relative to each other (e.g. human
and mouse protocadherin gene clusters) (37).
The presence of two distinct genes and readthrough
transcripts present some annotation challenges, especially
with regard to which gene the readthrough transcripts
should be associated with. In consultation with the HUGO
Gene Nomenclature Committee (HGNC), the CCDS collabor-
ators have recently agreed, in most circumstances, to rep-
resent the readthrough transcript as a separate locus.
Several protein-coding readthrough transcripts are repre-
sented in the CCDS data set, with each readthrough event
having more than one line of independent support to ex-
clude sporadic artifacts. Curation is currently ongoing and
has mostly been focused on human genes thus far; it is
expected that more readthrough transcripts will be
included in the CCDS data set following future builds. An
example is CCDS56237.1 representing the ARPC4-TTLL3
gene, which encodes a fusion protein that shares identity
with the products of both individual genes.
Discussion
CCDS curation guidelines were established to address spe-
cific annotation conflicts that were observed at a higher
frequency. These guidelines were guided by experimental
data with default options established to define ‘best prac-
tice’ approaches when experimental data is not readily
available. Establishment of CCDS curation guidelines has
helped to make the CCDS curation process more efficient
by reducing the number of conflicting votes and time spent
in discussion to reach a consensus agreement. In addition,
integration of these curation policies into the RefSeq and
HAVANA guidelines has resulted in increased consistency
for manually annotated CDS regions, with a corresponding
increase in the number of proteins tracked with a CCDS
ID, and a corresponding reduction in the number of new
annotations that end up in the Prospective CCDS report.
CCDS curation guidelines are fluid due to the increasing
biological research into the issues affecting the ability
to accurately represent the structure of genes mapped to
the reference genomes, as well as addition of new data
that can be used as evidence. Therefore, as biological
understanding of translation initiation, NMD and uORFs
increases, the curation policies will be reviewed and
updated. In the future, genome-wide data sets may
help more accurately determine what occurs, in vivo, for
each transcript rather than applying generalized rules.
Proteomics data could help confirm when alternate
in-frame translation start sites are used, or the translation
of uORFs.
A major limitation of the CCDS data set is that not all
protein-coding loci or coding splice variants are currently
represented in the CCDS data set. Although we have estab-
lished joint CCDS annotation guidelines, they address
specific issues as indicated above, and other annotation dif-
ferences remain. The lack of a CCDS ID for a given gene or
CDS could be due to differences regarding the project goals
for the RefSeq and HAVANA groups, support evidence
.............................................................................................................................................................................................................................................................................................
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protein-coding nature of a transcript or simply due to the
fact that one or both groups has not yet have annotated
the gene or a particular splice variant. The CCDS genome
annotation analysis process identifies proteins annotated
by any member of the collaboration for which annotation
is not consistent (and thus it will not gain a CCDS ID). These
are tracked as Prospective CCDS cases in the internal web-
site with a mechanism for curators to flag annotations that
can readily be added to the CCDS data set based on an
annotation addition or update by RefSeq or HAVANA.
Thus, the project work flow includes periodic focus by cur-
ators to proactively address protein-coding genes that lack
CCDS IDs; this ongoing curation is facilitated by the estab-
lished CCDS curation guidelines. Manual monitoring of the
Prospective CCDS queue indicates that the use of estab-
lished CCDS guidelines by RefSeq and HAVANA curation
staff is yielding more consistent CDS annotation.
Limitations in supporting data are more difficult to ad-
dress, such as the lack of sufficient transcript data to define
the full-length exon combination. Some protein annota-
tions are intentionally excluded from the CCDS data set
due to quality issues with the supporting transcripts or pub-
lished experimental data, such as retained introns, chimer-
ism or concerns based on a publication description on how
a cDNA was cloned, sequenced or assembled, or concerns
about the limitations of the experimental approach used.
However, for most supporting data, there is no reason to
suspect, or else there is insufficient information to deter-
mine, that there is a quality concern, and thus the quality of
the resulting CCDS representations rely heavily on the qual-
ity of the underlying primary data.
Since the CCDS data set represents genomic annotations,
quality issues with the reference genome sequence present
another challenge. This affects genes that are located in or
around gaps in the reference genome assembly, or where
the reference genome is misassembled, contains a frame-
shifting indel, premature stop codon or polymorphic
pseudogene and cannot represent the correct protein,
e.g. the human NBPF14 gene and polymorphic pseudogene
GPR33 (38). CCDS project collaborators report identified
problems with the human and mouse reference genome
sequence data to the Genome Reference Consortium
(GRC, http://www.ncbi.nlm.nih.gov/projects/genome/assem-
bly/grc/) (39) that investigates and makes a correction, if
deemed appropriate. Once the genome problem has been
corrected in a new assembly, the gene can then be repre-
sented in the CCDS data set, e.g. CCDS45604.1 representing
the human FXR2 gene.
It is important for other annotation groups and re-
searchers to understand both the process flow used to gen-
erate the CCDS data set and the curation guidelines applied
to the manually curated subset of the CCDS data set, as this
information guides interpretation and use of the data set.
User feedback indicates that the CCDS data set is a valued
definition of high confidence coding exons and it is used
in large-scale epigenomic studies, production of exon
arrays (40), the design of exome capture kits (41) and
the design of an in silico set of oligonucleotides (the
Human OligoExome) (42). The CCDS data set is also inte-
grated into the GENCODE (http://www.gencodegenes.org)
(4) gene annotation project (one of the projects of the
ENCODE consortium, http://www.genome.gov/10005107)
(43, 44).
Gene annotation continues to be essential for interpret-
ation of the functional elements of the genome, in the
study of genome and gene evolution, and for experimental
design. Comparative analysis is confounded by application
of different annotation standards to different genomes,
and thus we feel that the standards being established by
the CCDS collaboration should be considered in a wider
context. New sequencing technologies have greatly im-
proved the speed while significantly reducing the cost of
generating whole-genome sequence data; at the same time
new or improved assembly algorithms are more efficiently
assembling sequence data into genome assemblies (45).
This has resulted in a large expansion in the number of
species being sequenced, and this is anticipated to continue
to increase as there are a number of projects that aim to
sequence the genomes of numerous species such as the
Genome 10K Project (46). The cost of providing manual
curation support to annotate these genomes is prohibitive
and thus they will be annotated using computational pipe-
lines. As a data set that is more significantly curated
and subject to international agreement, we anticipate
future use of CCDS data as a quality assurance measure of
annotation results. In addition, the curation standards
being established for the CCDS project may guide further
refinements to computational pipelines to adhere with
CCDS project criteria.
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